...average cost per year for a patient to be $96,000. Fintepla is a derivative of amphetamine...

...review additional data for the candidate, an oral solution of low-dose fenfluramine, a derivative of amphetamine...

...full year of sales. Fintepla is an oral solution of low-dose fenfluramine, a derivative of amphetamine...

...seizures associated with Dravet syndrome was granted Priority Review. The oral low-dose solution of the amphetamine...

...associated with Dravet syndrome. Fintepla is an oral solution of low-dose fenfluramine, a derivative of amphetamine...

...treat Dravet syndrome. The therapy is an oral solution of low-dose fenfluramine, a derivative of amphetamine...

...treat Dravet syndrome. The therapy is an oral solution of low-dose fenfluramine, a derivative of amphetamine...

...for Dravet Syndrome" ). ZX008 is an oral solution of low-dose fenfluramine, a derivative of amphetamine...
...ZX008 Business: Neurology Molecular target: NA Description: Oral solution of low-dose fenfluramine, a derivative of amphetamine...

...Dravet Syndrome Candidate" ). ZX008 is an oral solution of low-dose fenfluramine, a derivative of amphetamine...

...that is expected to face generic competition in 2022-23. Mydayis, an extended-release formulation of mixed amphetamine...